A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Saved in:
| Title: | A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. |
|---|---|
| Authors: | Ewer K; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Rampling T; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Venkatraman N; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Bowyer G; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Wright D; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Lambe T; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Imoukhuede EB; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Payne R; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Fehling SK; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Strecker T; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Biedenkopf N; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Krähling V; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Tully CM; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Edwards NJ; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Bentley EM; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Samuel D; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Labbé G; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Jin J; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Gibani M; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Minhinnick A; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Wilkie M; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Poulton I; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Lella N; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Roberts R; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Hartnell F; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Bliss C; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Sierra-Davidson K; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Powlson J; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Berrie E; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Tedder R; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Roman F; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., De Ryck I; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Nicosia A; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Sullivan NJ; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Stanley DA; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Mbaya OT; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Ledgerwood JE; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Schwartz RM; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Siani L; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Colloca S; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Folgori A; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Di Marco S; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Cortese R; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Wright E; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Becker S; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Graham BS; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Koup RA; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Levine MM; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Volkmann A; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Chaplin P; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Pollard AJ; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Draper SJ; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Ballou WR; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Lawrie A; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Gilbert SC; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.)., Hill AV; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.). |
| Source: | The New England journal of medicine [N Engl J Med] 2016 Apr 28; Vol. 374 (17), pp. 1635-46. Date of Electronic Publication: 2015 Jan 28. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 25629663 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ewer+K%22">Ewer K</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Rampling+T%22">Rampling T</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Venkatraman+N%22">Venkatraman N</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Bowyer+G%22">Bowyer G</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Wright+D%22">Wright D</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Lambe+T%22">Lambe T</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Imoukhuede+EB%22">Imoukhuede EB</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Payne+R%22">Payne R</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Fehling+SK%22">Fehling SK</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Strecker+T%22">Strecker T</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Biedenkopf+N%22">Biedenkopf N</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Krähling+V%22">Krähling V</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Tully+CM%22">Tully CM</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Edwards+NJ%22">Edwards NJ</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Bentley+EM%22">Bentley EM</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Samuel+D%22">Samuel D</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Labbé+G%22">Labbé G</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Gibani+M%22">Gibani M</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Minhinnick+A%22">Minhinnick A</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Wilkie+M%22">Wilkie M</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Poulton+I%22">Poulton I</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Lella+N%22">Lella N</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Roberts+R%22">Roberts R</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Hartnell+F%22">Hartnell F</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Bliss+C%22">Bliss C</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Sierra-Davidson+K%22">Sierra-Davidson K</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Powlson+J%22">Powlson J</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Berrie+E%22">Berrie E</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Tedder+R%22">Tedder R</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Roman+F%22">Roman F</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22De+Ryck+I%22">De Ryck I</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Nicosia+A%22">Nicosia A</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Sullivan+NJ%22">Sullivan NJ</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Stanley+DA%22">Stanley DA</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Mbaya+OT%22">Mbaya OT</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Ledgerwood+JE%22">Ledgerwood JE</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Schwartz+RM%22">Schwartz RM</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Siani+L%22">Siani L</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Colloca+S%22">Colloca S</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Folgori+A%22">Folgori A</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Di+Marco+S%22">Di Marco S</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Cortese+R%22">Cortese R</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Wright+E%22">Wright E</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Becker+S%22">Becker S</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Graham+BS%22">Graham BS</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Koup+RA%22">Koup RA</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Levine+MM%22">Levine MM</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Volkmann+A%22">Volkmann A</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Chaplin+P%22">Chaplin P</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Pollard+AJ%22">Pollard AJ</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Draper+SJ%22">Draper SJ</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Ballou+WR%22">Ballou WR</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Lawrie+A%22">Lawrie A</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Gilbert+SC%22">Gilbert SC</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.).<br /><searchLink fieldCode="AU" term="%22Hill+AV%22">Hill AV</searchLink>; From the Jenner Institute and Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford (K.E., T.R., N.V., G.B., D.W., T.L., E.B.I., R.P., C.M.T., N.J.E., G.L., J.J., M.G., A.M., M.W., I.P., N.L., R.R., F.H., C.B., K.S.-D., J.P., E.B., A.J.P., S.J.D., A.L., S.C.G., A.V.S.H.), and Viral Pseudotype Unit, Faculty of Science and Technology, University of Westminster (E.M.B., E.W.), and Virus Reference Department, Public Health Agency (D.S., R.T.), London - all in the United Kingdom; the Institute of Virology, Philipps University Marburg (S.K.F., T.S., N.B., V.K., S.B.), and German Center for Infection Research, Partner Site Giessen-Marburg-Langen (S.B.), Marburg, and Bavarian Nordic, Martinsried (A.V., P.C.) - all in Germany; GlaxoSmithKline Biologicals, Rixensart, Belgium (F.R., I.D.R., W.R.B.); ReiThera, Rome (A.N., L.S., S.C., A.F., S.D.M.), and CEINGE and the Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples (A.N.) - both in Italy; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (N.J.S., D.A.S., O.T.M., J.E.L., R.M.S., B.S.G., R.A.K.), and the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore (M.M.L.) - both in Maryland; and Keires, Basel, Switzerland (R.C.). – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220255562%22">The New England journal of medicine</searchLink> [N Engl J Med] 2016 Apr 28; Vol. 374 (17), pp. 1635-46. <i>Date of Electronic Publication: </i>2015 Jan 28. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Massachusetts+Medical+Society%22">Massachusetts Medical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0255562 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1533-4406 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200284793%22">00284793 </searchLink><i>NLM ISO Abbreviation: </i>N Engl J Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25629663 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1056/NEJMoa1411627 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1635 Titles: – TitleFull: A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ewer K – PersonEntity: Name: NameFull: Rampling T – PersonEntity: Name: NameFull: Venkatraman N – PersonEntity: Name: NameFull: Bowyer G – PersonEntity: Name: NameFull: Wright D – PersonEntity: Name: NameFull: Lambe T – PersonEntity: Name: NameFull: Imoukhuede EB – PersonEntity: Name: NameFull: Payne R – PersonEntity: Name: NameFull: Fehling SK – PersonEntity: Name: NameFull: Strecker T – PersonEntity: Name: NameFull: Biedenkopf N – PersonEntity: Name: NameFull: Krähling V – PersonEntity: Name: NameFull: Tully CM – PersonEntity: Name: NameFull: Edwards NJ – PersonEntity: Name: NameFull: Bentley EM – PersonEntity: Name: NameFull: Samuel D – PersonEntity: Name: NameFull: Labbé G – PersonEntity: Name: NameFull: Jin J – PersonEntity: Name: NameFull: Gibani M – PersonEntity: Name: NameFull: Minhinnick A – PersonEntity: Name: NameFull: Wilkie M – PersonEntity: Name: NameFull: Poulton I – PersonEntity: Name: NameFull: Lella N – PersonEntity: Name: NameFull: Roberts R – PersonEntity: Name: NameFull: Hartnell F – PersonEntity: Name: NameFull: Bliss C – PersonEntity: Name: NameFull: Sierra-Davidson K – PersonEntity: Name: NameFull: Powlson J – PersonEntity: Name: NameFull: Berrie E – PersonEntity: Name: NameFull: Tedder R – PersonEntity: Name: NameFull: Roman F – PersonEntity: Name: NameFull: De Ryck I – PersonEntity: Name: NameFull: Nicosia A – PersonEntity: Name: NameFull: Sullivan NJ – PersonEntity: Name: NameFull: Stanley DA – PersonEntity: Name: NameFull: Mbaya OT – PersonEntity: Name: NameFull: Ledgerwood JE – PersonEntity: Name: NameFull: Schwartz RM – PersonEntity: Name: NameFull: Siani L – PersonEntity: Name: NameFull: Colloca S – PersonEntity: Name: NameFull: Folgori A – PersonEntity: Name: NameFull: Di Marco S – PersonEntity: Name: NameFull: Cortese R – PersonEntity: Name: NameFull: Wright E – PersonEntity: Name: NameFull: Becker S – PersonEntity: Name: NameFull: Graham BS – PersonEntity: Name: NameFull: Koup RA – PersonEntity: Name: NameFull: Levine MM – PersonEntity: Name: NameFull: Volkmann A – PersonEntity: Name: NameFull: Chaplin P – PersonEntity: Name: NameFull: Pollard AJ – PersonEntity: Name: NameFull: Draper SJ – PersonEntity: Name: NameFull: Ballou WR – PersonEntity: Name: NameFull: Lawrie A – PersonEntity: Name: NameFull: Gilbert SC – PersonEntity: Name: NameFull: Hill AV IsPartOfRelationships: – BibEntity: Dates: – D: 28 M: 04 Text: 2016 Apr 28 Type: published Y: 2016 Identifiers: – Type: issn-electronic Value: 1533-4406 Numbering: – Type: volume Value: 374 – Type: issue Value: 17 Titles: – TitleFull: The New England journal of medicine Type: main |
| ResultId | 1 |
